Literature DB >> 12600426

The value of a second transurethral resection in evaluating patients with bladder tumours.

Makram Miladi1, Michaël Peyromaure, Marc Zerbib, Djillali Saïghi, Bernard Debré.   

Abstract

OBJECTIVES: To evaluate the usefulness of a second transurethral resection for superficial and muscle-invasive bladder tumours.
METHODS: A review of the literature relevant to repeat resection for bladder tumours was conducted using Medline Services.
RESULTS: Transurethral resection of the bladder has two shortcomings: underestimating clinical stage, and overlooking other lesions. A second transurethral resection, when performed 2-6 weeks after the initial resection, corrects clinical staging errors in 9-49% of cases and detects residual tumour in 26-83% of cases. A second resection is particularly warranted for T1 tumours since 2-28% of them prove to be muscle-invasive, thus requiring a change in management. For muscle-invasive tumours, a second resection may be performed only if bladder sparing is being considered, as it helps to exclude the presence of tumour sites contra-indicating conservative treatment.
CONCLUSIONS: A second transurethral bladder resection may be warranted for T1 tumours, and for invasive tumours when a bladder preservation is planned. Copyright 2003 Elsevier Science B.V.

Entities:  

Mesh:

Year:  2003        PMID: 12600426     DOI: 10.1016/s0302-2838(03)00040-x

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  30 in total

1.  Bladder cancer: narrowing the gap between evidence and practice.

Authors:  Maha H A Hussain; David P Wood; Dean F Bajorin; Bernard H Bochner; Robert Dreicer; Donald L Lamm; Michael A O'Donnell; Arlene O Siefker-Radtke; Dan Theodorescu; Colin P Dinney
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

Review 2.  Urothelial carcinoma of the bladder: definition, treatment and future efforts.

Authors:  Sandip M Prasad; G Joel Decastro; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

3.  Repeated transurethral resection for non-muscle invasive bladder cancer.

Authors:  Ming Cao; Guoliang Yang; Jiahua Pan; Jie Sun; Qi Chen; Yonghui Chen; Haige Chen; Wei Xue
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy.

Authors:  Jacob T Ark; Kirk A Keegan; Daniel A Barocas; Todd M Morgan; Matthew J Resnick; Chaochen You; Michael S Cookson; David F Penson; Rodney Davis; Peter E Clark; Joseph A Smith; Sam S Chang
Journal:  BJU Int       Date:  2014-04-03       Impact factor: 5.588

5.  Best practice in the treatment of nonmuscle invasive bladder cancer.

Authors:  Anastasios Anastasiadis; Theo M de Reijke
Journal:  Ther Adv Urol       Date:  2012-02

Review 6.  Optimal treatment of non-muscle invasive urothelial carcinoma including perioperative management revisited.

Authors:  Matthew J Pagano; Gina Badalato; James M McKiernan
Journal:  Curr Urol Rep       Date:  2014-11       Impact factor: 3.092

7.  Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness.

Authors:  Shuichiro Kobayashi; Fumitaka Koga; Soichiro Yoshida; Hitoshi Masuda; Chikako Ishii; Hiroshi Tanaka; Yoshinobu Komai; Minato Yokoyama; Kazutaka Saito; Yasuhisa Fujii; Satoru Kawakami; Kazunori Kihara
Journal:  Eur Radiol       Date:  2011-06-18       Impact factor: 5.315

Review 8.  Risk-adapted strategy for the kidney-sparing management of upper tract tumours.

Authors:  Thomas Seisen; Pierre Colin; Morgan Rouprêt
Journal:  Nat Rev Urol       Date:  2015-02-24       Impact factor: 14.432

9.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

10.  [Diagnosis of urothelial carcinoma].

Authors:  A Karl; D Zaak; D Tilki; E Hungerhuber; M Staehler; S Denzinger; P Stanislaus; S Tritschler; F Strittmatter; C Stief; M Burger
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.